TITLE: STIMULATION OF THE P2Y $_1$ RECEPTOR UPREGULATES NTPDase1 IN HUMAN RETINAL PIGMENT EPITHELIAL CELLS

Authors: Wennan Lu, David Reigada, Jean Sévigny, and Claire H. Mitchell

Author affiliation: Department of Physiology, University of Pennsylvania School of Medicine, 3700 Hamilton Walk, Philadelphia, PA 19104-6085 (WL, DR, CHM) and Centre de Recherche en Rhumatologie et Immunologie, Centre Hospitalier Universitaire de Québec, Université Laval, Québec, QC, Canada G1V 4G2 (JS)

JPET Fast Forward. Published on July 12, 2007 as DOI: 10.1124/jpet.107.124545 This article has not been copyedited and formatted. The final version may differ from this version.

JPET #124545

Running Title: NTPDase1 upregulation by P2Y₁ receptor

Corresponding Author: Dr. Claire H. Mitchell, Department of Physiology, University of Pennsylvania,

Downloaded from jpet.aspetjournals.org at ASPET Journals on April 19, 2024

3700 Hamilton Walk, Philadelphia, PA 19104-6085, Tel. 215 573-2176; Fax. 215 573-5851,

E-mail:chm@mail.med.upenn.edu

Number of text pages:15

Number of tables: 0

Number of figures: 5

Number of References: 41

Number of words in

Abstract: 250

Introduction: 557

Discussion: 1075

Non-standard abbreviations: CT, cycle threshold; DMEM, Dulbecco's modified Eagles medium; eNPP,

ectonucleotide pyrophosphatase/phosphodiesterase; FBS, fetal bovine serum; HEPES, N-2-

hydroxyethylpiperazine-N'-2-ethanesulfonic acid; MRS2179, N6-methyl-2'-deoxyadenosine-3',5'-

bisphosphate; MRS2365, (N)-methanocarba-2MeSADP; MRS2500, 2-iodo-N⁶-methyl-(N)-methanocarba-

2'-deoxyadenosine 3',5'-bisphosphate; NMDA, N-methyl-D-aspartic acid; NTPDase, nucleoside

triphosphate diphosphohydrolase; oATP, oxidized ATP; PVDF, polyvinylidine difluoride; RB2, Reactive

Blue 2; RPE, retinal pigment epithelium.

Section: Neuropharmacology

2

Abstract

Stimulation of receptors for either ATP or adenosine leads to physiologic changes in retinal pigment epithelial (RPE) cells that may influence their relationship to the adjacent photoreceptors. The nucleoside triphosphate diphosphohydrolase-1 (NTPDase1) ectoenzyme catalyzes dephosphorylation of ATP and ADP to AMP. While NTPDase1 can consequently control the balance between ATP and adenosine, it is unclear how its expression and activity are regulated. Classic negative feedback theory predicts an increase in enzyme activity in response to enhanced exposure to substrate. This study asked whether exposure to ATP increases NTPDase1 activity in RPE cells. While levels of NTPDase1 mRNA and protein in cultured human ARPE-19 cells were generally low under control conditions, exposure to slowly-hydrolyzable ATPγS led to a time-dependent increase in NTPDase1 mRNA level that was accompanied by a rise in levels of the functional 78 kD protein. Neither NTPDase2 nor NTPDase3 message was elevated by ATPyS. The ATPase activity of cells increased in parallel, indicating the upregulation of NTPDase1 was functionally relevant. The upregulation of NTPDase1 protein was partially blocked by P2Y₁ receptor inhibitors MRS2179 and MRS2500, and increased by P2Y₁ receptor agonist MRS2365. In conclusion, prolonged exposure to extracellular ATPγS increased NTPDase1 message and protein levels and increased ectoATPase activity. This upregulation reflects a feedback circuit, mediated at least in part by the P2Y₁ receptor, to regulate levels of extracellular purines in subretinal space. NTPDase1 levels may thus serve as an index for increased extracellular ATP levels under certain pathologic conditions, although other mechanisms could also contribute.

Introduction

Extracellular ATP and adenosine act at distinct receptors to mediate discrete actions in many tissues (Bucheimer and Linden, 2004). The two transmitters can act as a balanced pair, with diverse effects resulting from their activation of different receptors (Zhang et al., 2006b). The corresponding effects on cell physiology are influenced by the relative availability of each purine. P2 receptors for ATP are typically stimulated by ATP released from cells via physiologic mechanisms (Schwiebert, 2001; Lazarowski et al., 2003), while the adenosine capable of stimulating P1 receptors is frequently produced from the consecutive dephosphorylation of ATP (Dubyak and el-Moatassim, 1993). The extracellular enzymes that mediate this dephosphorylation can dramatically alter responsiveness by simultaneously removing ATP and producing adenosine. It follows that regulation of these enzymes offers great potential to alter the balance of purines and coordinate their effects.

The retinal pigment epithelium (RPE) lies adjacent to the photoreceptors in the posterior eye. Short and long-term communication between the two cell types is necessary for optimal visual function (Strauss, 2005). Adenosine and ATP can both modulate this interaction by stimulating P1 and P2 receptors, respectively (Mitchell and Reigada, In press). For example, activation of the P2Y₂ receptor for ATP on the RPE apical membrane elevates Ca²⁺ and enhances fluid movement across the tissue, thus helping to keep photoreceptors in place (Peterson et al., 1997; Maminishkis et al., 2002). Stimulation of an A₂ receptor for adenosine decreases the phagocytosis of photoreceptor outer segments by the RPE (Gregory et al., 1994).

Level of purine agonists in the subretinal space between the RPE and photoreceptors are regulated by various mechanisms. The RPE itself releases ATP into the subretinal space in response to NMDA receptor activation, chemical ischemia, cell swelling and other stimuli (Mitchell, 2001; Reigada and Mitchell, 2005; Reigada et al., 2006a; Mitchell and Reigada, In press). Multiple nucleotidases capable of converting the released ATP into adenosine have been identified. Ecto-5'-nucleotidase (CD73), which converts AMP to adenosine, was recently localized to the apical membrane of RPE cells, with enzyme activity decreased following stimulation of the α1 epinephrine receptor (Reigada et al., 2006b). RPE cells

are also capable of degrading extracellular ATP, with the cells expressing multiple ATPase enzymes. Message for eNPP1, eNPP2 and eNPP3, as well as NTPDase2 and NTPDase3 were clearly detected in cultured human ARPE-19 cells (Reigada et al., 2005). However, message for NTPDase1 was detected only occasionally, with most trials failing to pick up any PCR product.

The variable presence of NTPDase1 suggested that expression of the enzyme in RPE cells was regulated. Exposure to ATP has been shown to increase ectonucleotidase activity (Wiendl et al., 1998), although the specific identity of the contributing enzyme(s) has not been determined. As NTPDase1 uses ATP as a primary substrate, and as the levels of ATP bathing cells can be modified by a variety of environmental and experimental conditions (Grygorczyk and Hanrahan, 1997), we asked whether the presence of ATP in the bath was responsible for the appearance of the enzyme. As the dephosphorylation of ATP by ectonucleotidases would severely limit its half-life, ATPγS was used to prolonging availability of the nucleotide, as the replacement of oxygen with sulfur on the terminal phosphate greatly slows the hydrolysis of ATPγS with respect to ATP. Changes in NTPDase1 levels were examined on molecular, protein and functional levels and demonstrate physiological regulation of the enzyme.

Methods

Cell Culture and Treatment Regime – The human ARPE-19 cell line was obtained from the American Type Culture Collection (Manassas, VA) and grown grown in a 1:1 mixture of DMEM and Ham's F12 medium with 3 mM L-glutamine, 100 units/ml penicillin, 100 ug/ml streptomycin and 2.5 mg/ml Fungizone (all Invitrogen Corp, Carlsbad, CA) and 10% FBS (HyClone Laboratories, Inc., Logan, UT) as described (Reigada et al., 2005). Cells were grown for a total of 14-16 days, with confluence reached after 5-8 days. Cells grown for less time gave less consistent results. Cells were maintained for indicated times in growth medium containing 100 μM ATPγS or P2Y₁ agonists. For the 48 hrs preincubation time, the medium was replaced with fresh ATPyS solution after 24 hrs. Solution was replaced with growth medium alone at the same time points in controls. P2 inhibitors were added 10 min before ATPyS. RT-PCR – Total RNA was extracted from ARPE-19 cells using the Trizol reagent (Invitrogen, Corp.). Oligo dTs were used to reverse transcribe 2µg of total RNA at 42°C for 50 min using SuperScript II RT (Invitrogen Corp). Increasing concentrations of cDNA were used for semi-quantitative RT-PCR. β-actin was selected as an endogenous internal standard gene. The primers used were designed to human 5'-CTACCCCTTTGACTTCCAGG -3'. 5'-NTPDase1 (sense: anti-sense: GCACACTGGGAGTAAGGGC-3'; Macvector Program, Oxford Molecular Group/Accelrys, Burlington, MA; Reigada et al., 2005); NTPDase2 (sense: 5'- TGGAGGCAGCCGCAGTGAATGT -3', anti-sense: GGAGGCGAAGAGCAGCAGGAGGAC; Wood et al., 2002) NTPDase3 sense:5'-AGCCTGGTCTCTTGGCTACA-3', antisense: 5'-ACCCCAGGCTGACTCTAAGCA -3'; Primer3 software, http://frodo.wi.mit.edu/cgi-bin/primer3/primer3 www.cgi) and B-actin (sense: 5'-GGACTTCGAGCAAGAGATGG-3' and antisense: 5'- AGCACTGTGTTGGCGTACAG-3'; Primer3). The predicted amplification products were 558, 300, 271 and 244 bp for the NTPDase1, NTPDase2, NTPDase3 and actin primer pairs, respectively. The amplification conditions were 1 min at 95°C, 1 min at 58°C, and 1 min at 72°C. This cycle was repeated 33-35 times for the NTPDases and 26 times for βactin as initial trials determined that the PCR products for the later increased linearly between 23 and 33 cycles. In both cases, final extension was carried out at 72°C for 10 min. To control for genomic

contamination, parallel PCR reactions were performed using cDNA that had not been reverse transcribed. The reaction products were separated on a 1% agarose gel including 10 ng/mL ethidium bromide and photographed using an ultraviolet transilluminator (Fisher Scientific, Suwanee, GA.). Bands were scanned (Hewlett Packard Scanjet 3570c; Hewlett Packard Corp., Palo Alto, CA) and quantified with ImagePro Plus software (Media Cybernetics, Silver Spring, MD). The lack of increase in message for NTPDase2 and NTPDase3 was seen in two independent samples.

Real-time PCR - Real-time experiments were carried out in a Stratagene Mx3000P system (Stratagene Corp., Cedar Creek, TX). Total RNA was isolated as described above. Each PCR reaction contained 1 µl of RT product (cDNA samples were first diluted 1:10), 0.15 µM of each primer, 10 µl of 2× Brilliant SYBR Green OPCR Master Mix, 300 nM of reference dye (all Stratagene Corp.). Following a 95°C denaturation for 10 min, the reactions underwent 40 cycles of : 95°C for 30 sec, 58°C for 1 min, and 72°C for 1 min. New primers were chosen to give a smaller product appropriate for real-time PCR; primers for human NTPDase1 amplification were 5' - CAGGGACCCATGCTTTCATCC - 3' and 5' -GCTGGAATGGAAGAGTCATCTCA 3' (Primer bank, http://pga.mgh.harvard.edu/cgibin/primerbank/search.cgi; 104 bp) and for β-actin: 5' - CTCCTCCTGAGCGCAAGTACTC - 3' and 5' -TCGTCATACTCCTGCTTGCTGAT - 3'; (101 bp). Again, specificity for the NTPDase1 primers was confirmed using BLAST analysis. Three replicates of each reaction were performed and each run included a no-template control. The CT was determined when the level of fluorescence from accumulating amplicons crossed a threshold assigned during the period of linear growth. Relative starting mRNA template concentrations of each sample were calculated using the comparative delta-delta CT method for relative quantification as done previously (Zhang et al., 2006a). Briefly, CT values for the βactin gene were subtracted from that of the NTPDase1 gene for samples treated with control (\(\Delta CT cont \)) or ATPγS (ΔCTATPγS) solutions. The mean corrected difference of CT between control and ATPγS-treated cells was defined as $\Delta CTATP\gamma S$ - $\Delta CTcont$ (mean $\Delta\Delta CT$). Additional replicates were performed using the ABI 7500 (Applied Biosystems, Foster City, CA) shared by the Vision Research Core of the University of Pennsylvania using the same primers and analogous protocols.

Western blots – ARPE-19 cells were washed twice with cold Dulbecco's Phosphate-Buffered Saline (PBS; Invitrogen Corp.), and lysed in buffer containing 50 mM Tris-HCl, 150 mM NaCl, protease inhibitor cocktail (Complete; Roche Diagnostics, Germany), 1% Triton X-100, 0.1% SDS, and 10% glycerol. The samples were sonicated and cleared by centrifugation (10,000g) for 30 min at 4°C. The protein concentrates were determined using the bicinchoninic acid protein assay reagent (Pierce, Rockford, IL). Homogenate containing 60 μg of protein was separated using conventional SDS-PAGE under non-reducing conditions, and transferred to a PVDF membrane. Non-specific binding was blocked with 5% nonfat dried milk for 1 hr at 25°C. Blots were then incubated with a mouse monoclonal antibody against human NTPDase1, BU61 (1μg/ml; Ancell Corp., Bayport, MN) overnight at 4°C. This was followed by incubation with anti-mouse IgG conjugated with horseradish peroxidase (1:5000 dilution; Amersham Biosciences Corp., Arlington Heights, IL) at 25°C for 1 hr and developed by chemiluminescence detection (ECL detection system; Amersham Biosciences Corp.). ImagePro Plus software was used to quantify the intensity of the specific bands as above.

For membrane purified extracts, cells were homogenized in 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2mM EDTA and protease inhibitor cocktail. Nuclei and cell debris were removed from the homogenate by centrifugation at 10,000 × g for 15 min at 4 °C. The resulting supernatant was centrifuged at 40,000 × g for 35 min at 4 °C. The membrane pellet was solubilized in buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.5% Triton X-100, protease inhibitor cocktail) for a minimum of 1 hr at 4 °C.

Measurement of ATP hydrolysis – ARPE-19 cells were cultured in 96-well white plates with clear bottoms (Corning Inc., Corning, NY) to confluence. Cells were washed and 90 μl isotonic buffer containing 1 μM ATP was added to the wells immediately before recording began. Isotonic buffer contained (in mM) 105 NaCl; 5 KCl; 6 HEPES Acid; 4 NaHEPES; 5 NaHCO₃; 60 mannitol; 5 glucose; 0.5 MgCl₂; 1.3 CaCl₂, at pH 7.4. The plate was placed into a luminometer (Luminoskan Ascent, Labsystems; Franklin, MA) and 10 μl of luciferin-luciferase solution was injected into each well using the internal injector as described previously (Reigada and Mitchell, 2005). Luminescence levels were measured every 60 sec for 3 hrs, with an integration time of 100 msec for each well.

JPET Fast Forward. Published on July 12, 2007 as DOI: 10.1124/jpet.107.124545 This article has not been copyedited and formatted. The final version may differ from this version.

JPET #124545

Materials and analysis – MRS2500 and MRS2365 were obtained from Tocris Bioscience, (Ellisville, MO). Information concerning the structure and synthesis of these compounds is available at MRS2500 (Kim et al, 2003) and MRS2365 (Chhatriwala et al., 2004). All other materials were from the Sigma Chemical Corp. (St Louis, MO) unless otherwise noted. Statistical analysis was performed using unpaired Students t-test or an ANOVA test with appropriate post-hoc test. Time constants (τ) of ATP hydrolysis were calculated by fitting each individual record to an exponential decay curve y=ae^(-bx) using Sigmaplot Software (Systat Software Inc., Richmond, CA), with τ =1/b.

Results

Upregulation of NTPDase1 message

Exposure of ARPE-19 cells to $100 \,\mu\text{M}$ ATP γ S for 48 hrs enhanced expression of NTPDase1 message in three separate trials using standard PCR, as defined by the presence of a bright band at the expected 558 bp in cells treated with ATP γ S and its absence in control cells. To strengthen the analysis, the amount of PCR-amplified product was analyzed as a function of starting cDNA. The densitometric values of the NTPDase1 amplification products increased linearly with the amount of reverse transcribed cDNA added (Fig. 1A, B). In contrast, no bands were detected using any concentration of cDNA obtained from cells grown in control medium. Similar results were found using message extracted from three independent sets of cells in the presence and absence to 100 μ M ATP γ S. To ensure that this increase in message after exposure to ATP γ S was specific for NTPDase1, the analysis was repeated using primers for β -actin as an internal control. The amount of β -actin product was the same for ATP γ S treated and control cells regardless of the amount of starting cDNA (Fig. 1C, D). No increase in message for either NTPDase2 or NTPDase3 was found in cells exposed to 100 μ M ATP γ S for 48 hrs, even though NTPDase1 was substantially elevated in the same samples (not shown). In all cases, no product was detected when reverse transcriptase was omitted from the reaction.

The time-course of upregulation was examined by collecting RNA from cells exposed to ATP γ S for 0, 1, 3, 6, 12, 24 and 48 hrs. PCR product was first detected in material obtained after 12 hrs exposure (Fig 1E, F). In contrast, levels of β -actin did not vary much with the duration of exposure. Similar results were obtained in three independent sets of cells exposed to ATP γ S for the indicated durations. In the set shown, levels of message were highest at 12 hrs and declined slightly afterwards, but still remained >100 fold greater than control after 48 hrs of treatment. In one trial, levels at 12 hrs were 80% of the maximum found at 24 hrs, while in the third set levels at 12 hrs were 20% of those found at 24 hrs. While message was first detected in the 12 hr sample in all cases, this variation in relative amount suggests that the greatest increase in message occurs near the 12 hr point.

The semi-quantitative PCR above suggested that exposure of RPE cells to ATP γ S led to an increase in mRNA for NTPDase1. More quantitative evidence for this transcriptional regulation was sought using real-time PCR. Real-time PCR was performed with cDNA isolated from cells exposed to 100 μ M ATP γ S and control solution for 48 hrs. Message for NTPDase1 was detected at a much lower number of amplification cycles in cells treated with ATP γ S than with control solution, indicating a larger amount of starting message (Fig. 2). Treatment with ATP γ S had no effect on detection of β -actin message. When adjusted for the amount of β -actin, message from ATP γ S-treated cells crossed the threshold after 8.42 cycles while that from control cells crossed at 18.17 cycles, giving a mean $\Delta\Delta$ CT of 9.75. There was no observable amplification without template. A similar increase was seen using cells from three independent trials.

Upregulation of NTPDase1 protein

The relative expression of NTPDase1 was examined using Western blotting techniques to determine if the increase in transcription led to a corresponding increase in protein. Protein from whole cell extracts was run and probed with the NTPDase1 monoclonal anti-human antibody BU61. While nothing was detected from cells under control conditions, protein from cells exposed to ATPyS for 48 hrs showed a clear, single band of 78 kD (Fig 3A). This size band corresponds to the functional monomeric glycosylated form of NTPDase1 (Sevigny et al., 1997). Similar increases were found in three independent trials following 48 hrs treatment with 100 µM ATPyS. The 78kDa band was also detected in a fraction specifically enriched in membrane proteins (Fig. 3B), suggesting the increase could have functional implications.

Further analysis was performed to determine the time course of the increase in protein. Exposure to ATPγS for 12, 24 and 48 hrs led to a corresponding increase in band intensity (Fig. 3C). Densitometric quantification of the blot supported this observation, and indicated the biggest jump in protein occurred between 12 and 24 hrs after exposure to ATPγS began (Fig. 3D). As levels of protein were similar for 24 and 48 hrs exposure, subsequent experiments were performed at 24 hrs. In total, band intensity increased

in 14 preparations after 24 hrs exposure to 100 μM ATPγS. Band intensity was usually below the limits of detection in material from cells not exposed to ATPγS. Faint bands were found in protein from untreated control cells in 3 of the 14 preparations. The presence of NTPDase1 protein in some controls but not others is consistent with the occasional presence of NTPDase1 found previously (Reigada et al., 2005).

Upregulation of ATP hydrolysis

Functional analysis of extracellular ATP hydrolysis was performed to determine whether the increases in NTPDase1 mRNA and protein levels were accompanied by an increase in biochemical activity. The time-course of ATP dephosphorylation was monitored after injection of 1 uM hydrolyzable ATP into the bath, as this concentration is below that previously demonstrated to trigger an ATPmediated ATP release in these cells (Reigada et al., 2005). While extracellular ATP was hydrolyzed by control cells, this enzymatic activity was substantially enhanced in cells treated with 100 µM ATPyS (Fig. 4A). Levels of ATP bathing control cells dropped to 23.9±2.9% of the initial values after 3 hrs of enzymatic reaction, but this fell to 2.1±0.5% in cells exposed to ATPγS for 48 hrs. Exposure to ATPγS for intermediate times had intermediate effects on hydrolysis, with 6.9±0.9% and 4.3±0.4% of ATP remaining after 15 hrs and 24 hrs respectively. The speed of decay was also enhanced, with the time constant for hydrolysis falling with increased exposure to ATP\(gamma\)S (Fig. 4B). The majority of the increase in ATPase activity occurred in the first 24 hrs, in agreement with the increase in protein and message (Fig. 3B). In total, the mean time constant fell from $5387 \pm 435 \text{ s}^{-1}$ to $3515 \pm 250 \text{ s}^{-1}$ after 48 h preincubation with ATPyS (n=45-50 wells from 3 independent trials, p<0.0002). The closeness of the initial luminescence values indicated that residual ATP from the ATPγS pretreatment was not affecting the functional assay. In one set of experiments, ATPyS treatment failed to enhance activity, although mRNA for NTPDase1 was already elevated in untreated controls and did not increase further with ATPyS treatment.

P2Y₁ receptor and upregulation of NTPDase1

We hypothesized that stimulation of P2 receptors present on these cells might initiate the changes that led to increased transcription of NTPDase1 message and elevated levels of protein. The ability of P2 antagonists to inhibit this upregulation was quantified from the 78 kDa band on Western blots, as this provided post-translational information specifically about the functional form of NTPDase1. Two relatively non-specific antagonists were initially tested. Antagonists oATP (100 μ M) and RB2 (50 μ M) were added to cells 10 min before ATP γ S, and proteins extracted 24 hrs later. Levels of NTPDase1 were decreased in all 4 trials with oATP, with a mean decrease of 25 ± 11 % (Fig. 5A). The effect of RB2 was more variable, with levels decreasing by over 90%, in one trial, but increasing by 250% in another, giving a non-significant change overall (Fig. 5B).

The effect of oATP, and perhaps RB2, suggested some type of P2 receptor involvement. The contribution from the P2Y₁ receptor in particular was pursued for several reasons. Although oATP has traditionally been used as a P2X₇ receptor inhibitor and is now recognized to have actions as a general P2X blocker, it also has distinct effects on the P2Y₁ receptor (Beigi et al., 2003). Previous analysis has indicated the presence of the P2Y₁ receptor in these cells on a molecular and functional level (Fries et al., 2004; Reigada et al., 2005), and the recent availability of specific pharmacologic tools for the P2Y₁ receptor has enabled a more definitive analysis. Addition of the P2Y₁ antagonist MRS2179 to cells 10 min before ATPyS inhibited the response in 7 out of 7 trials. In total, the expression of NTPDase1 in cells treated with MRS2179 (100 μM) was reduced by 58% as compared to cells treated with ATPγS alone (Fig. 5C). While MRS2179 is 3 orders of magnitude more selectivite for the P2Y₁ receptor than the P2Y₂, P2Y₄, P2Y₆ and P2Y₁₁ receptors (Boyer et al., 1998; von Kugelgen, 2006), the compound is not particularly stable (Baurand and Gachet, 2003; Hechler et al., 2006) and requires relatively high levels for effective block over extended periods. In contrast, the recently available inhibitor MRS2500 is substantially more stable and effective in the low nanomolar range, with no binding or action at P2Y₂, P2Y₁₂ or avian P2Y receptors (Kim et al., 2003; Hechler et al., 2006; Houston et al., 2006). Treatment of cells with 10 nM MRS2500 reduced the amount of NTPDase1 by over 30% (Fig. 5D).

The block by both MRS2179 and MRS2500 implicated the P2Y₁ receptor, but relative ineffectiveness of ATP at the P2Y₁ receptor, combined with the potential for contamination of commercially obtained ATP γ S with other nucleotide products, led us to seek additional confirmation with a more specific agonist (von Kugelgen, 2006). The agonist MRS2365 is highly specific for the P2Y₁ receptor; it was reported to have no activity at the P2Y₁₂ receptor and very little at the P2Y₁₃ receptor, while stimulating the P2Y₁ receptor with an EC₅₀ in the low nanomolar range (Chhatriwala et al., 2004). At 10 nM, MRS2365 significantly increased NTPDase1 levels 14 fold over control (n=5). Increasing MRS2365 to 100 nM raised NTPDase1 levels 25-fold over control (Fig. 5E), although the upregulation by MRS2365 was not additive with that of ATP γ S. The increase by 2MeSATP (100 μ M) was not significant, perhaps due to the ability of NTPDase1 to hydrolyze this agonist (Picher et al., 1996).

Discussion

This study shows that prolonged exposure to ATP γ S increased transcription of NTPDase1 in human ARPE-19 cells. This increase in mRNA was accompanied by an increase in NTPDase1 protein and in the rate of extracellular ATP hydrolysis. This response was mediated, at least in part, by the P2Y₁ receptor, and may reflect the need for cells to maintain low levels of extracellular nucleotides.

The E-NTPDase family is composed of eight members and four of them, NTPDase1, 2, 3, and 8 are dominant ectonucleotidases that dephosphorylate extracellular nucleotides (Bigonnesse et al., 2004). NTPDase1 catalyzes the dual dephosphorylation of ATP and ADP to AMP plus inorganic phosphorus (Kaczmarek et al., 1996; Robson et al., 2006). NTPDase1 is an acidic glycoprotein with a molecular mass of 78 kDa that contains two transmembrane regions and several potential glycosylation sites (Sevigny et al., 1997). A truncated 54kDa band is occasionally observed, corresponding to a C-terminal portion created by proteolytic digestion of the larger 78 kDa form (Sevigny et al., 1995; Schulte am Esch et al., 1999; Lemmens et al., 2000). The detection of a 78 kDa band with the monoclonal antibody BU61 corresponds to the active monomeric form of the enzyme and is consistent with an increase in the ATPase activity of RPE cells after treatment with ATPyS.

The ability of MRS2179 and MRS2500 to inhibit the upregulation of NTPDase1 by ATPγS, combined with the increase induced by MRS2365, strongly implicates the P2Y₁ receptor in the control of enzyme levels. The shared utilization of both tri- and diphosphate adenines makes the P2Y₁ receptor well matched to regulate NTPDase1. ADP is considerable more effective at the P2Y₁ receptor than is ATP (von Kugelgen, 2006), while ADP is hydrolyzed more effectively by NTPDase1 than other members of the E-NTPDase family (Kaczmarek et al., 1996). Stimulation of the P2Y₁ receptor is also affected by the expression of NTPDase1 (Alvarado-Castillo et al., 2005). A contribution from other P2 receptors in the upreguation of NTPDase1 is possible as relatively high levels of MRS2179 and MRS2500 inhibited only half the response to ATPγS, while a maximally effective concentration of MRS2365 the increased NTPDase1 levels to only half that of ATPγS (Chhatriwala et al., 2004). However, instability of MRS2365 over the course of 24 hours may have led to a sub-maximal response. The second-messenger pathways

linking receptor stimulation with transcriptional control are presently unknown, but stimulation of the $P2Y_1$ receptor in myotubes can upregulate expression of acetylcholine esterase through a pathway involving intracellular Ca^{2+} , protein kinase C and the transcription factor Elk-1 (Choi et al., 2003), while activation of the $P2Y_1$ receptor in ARPE-19 cells increases intracellular Ca^{2+} (Reigada et al., 2005). Whether this rise in Ca^{2+} is necessary for the upregulation of NTPDase1 remains to be determined.

It is possible that other members of the E-NTPDase family, or those of the eNPP family, are also upregulated after treatment with ATPγS. Ogilvie and colleagues found previous exposure to ATP altered the degradation of numerous nucleotides (Wiendl et al., 1998). However, the consistently high expression of some of these other enzymes in ARPE-19 cells under unstimulated conditions predicts a smaller relative change, (Reigada et al., 2005), perhaps explaining why neither NTPDase2 not NTPDase3 were upregulated by ATPγS in our hands. As ATPγS is hydrolyzed slowly, it is also possible that some of the effects are initiated by ADP. We feel these results may open up an exciting area of investigation into how different nucleotide species stimulate purine receptors to alter expression of nucleotidase enzymes.

Previous examination of the ecto-nucleotidases in RPE cells found levels of NTPDase1 were variable, with mRNA for the enzyme detected only occasionally (Reigada et al., 2005). While it is not possible to examine the reasons for this variability in retrospect, changes in the levels of extracellular ATP may have contributed, and release of ATP is exquisitely sensitive to handling (Grygorczyk and Hanrahan, 1997). Conditions of cell growth may also have modified expression, as initial investigations indicate that enzyme expression was more reliably regulated when cells were grown for two weeks as opposed to the one week used in earlier studies. Even with prolonged growth, however, NTPDase1 was occasionally present in control cells, indicating additional yet unknown parameters may influence expression. The dynamic regulation of NTPDase1 levels does emphasize caution when interpreting evidence for the presence or absence of the enzyme in either cultured or fresh cells.

Cells would not be exposed to ATPγS *in vivo*, of course, but to a sustained supply of fresh, excess ATP released into the extracellular space. As increased protein and ATP hydrolysis was observed after 12 hrs, this feedback system may have implications for the physiological processes regulated by the

light/dark cycle in subretinal space. Glutamate is released by photoreceptors in the dark, and stimulation of an NMDA receptor for glutamate on the apical surface of the RPE leads to a rapid increase in the levels of extracellular ATP (Mitchell, 2001; Reigada and Mitchell, 2005; Reigada et al., 2006a). The present findings suggest this increased ATP in subretinal space would upregulate NTPDase1 levels 12 hrs later, thus altering the dynamics of purinergic signaling in the light.

The causal link between ATPγS and NTPDase1 upregulation above supports the role of excess ATP in several pathologic conditions. For example, changes in nucleotidase activity have been observed after epileptic seizures (Bonan et al., 2000) and global cerebral ischemia (Schetinger et al., 1994), and NTPDase1 regulation at the transcriptional level has been observed in response to transient forebrain ischemia (Braun et al., 1998) and excess noise in the cochlea (Vlajkovic et al., 2004). The rise in the enzyme was often assumed to occur in response to elevated extracellular ATP, but as far as we are aware this has not been directly shown until now. Although identification of the specific enzyme involved in these cases is needed, these observations, and those in epidermoid carcinoma cells (Wiendl et al., 1998), make it unlikely that upregulation of NTPDase1 is restricted to RPE cells.

In addition to confirming a trigger for upregulation of NTPDase1, the demonstration that ATPγS enhanced NTPDase1 levels suggests that the enzyme could provide diagnostic information. Measurements of extracellular ATP are frequently difficult to make in vivo, complicated by high intracellular levels, the release of ATP following physiologic manipulation (Grygorczyk and Hanrahan, 1997), and the restrictive extracellular microenvironment. Levels of NTPDase1 might serve as an index for prolonged increases in extracellular ATP concentrations, although contribution of other mechanisms to enzyme levels is of course, always possible.

JPET Fast Forward. Published on July 12, 2007 as DOI: 10.1124/jpet.107.124545 This article has not been copyedited and formatted. The final version may differ from this version.

JPET #124545

Acknowledgments: The authors are grateful to Richard Stone, Alan Laties and Mortimer Civan for useful discussions, to Alex Laties for technical help, and to Kenneth Jacobson for his advice on the pharmacology on the P2Y₁ receptor.

References

- Alvarado-Castillo C, Harden TK and Boyer JL (2005) Regulation of P2Y1 receptor-mediated signaling by the ectonucleoside triphosphate diphosphohydrolase isozymes NTPDase1 and NTPDase2. *Mol Pharmacol* **67**:114-122.
- Baurand A and Gachet C (2003) The P2Y1 receptor as a target for new antithrombotic drugs: a review of the P2Y1 antagonist MRS-2179. *Cardiovasc Drug Rev* **21**:67-76.
- Beigi RD, Kertesy SB, Aquilina G and Dubyak GR (2003) Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. *Br J Pharmacol* **140**:507-519.
- Bigonnesse F, Levesque SA, Kukulski F, Lecka J, Robson SC, Fernandes MJ and Sevigny J (2004)

 Cloning and characterization of mouse nucleoside triphosphate diphosphohydrolase-8. *Biochem*43:5511-5519.
- Bonan CD, Walz R, Pereira GS, Worm PV, Battastini AM, Cavalheiro EA, Izquierdo I and Sarkis JJ (2000) Changes in synaptosomal ectonucleotidase activities in two rat models of temporal lobe epilepsy. *Epilepsy Res* **39**:229-238.
- Boyer JL, Mohanram A, Camaioni E, Jacobson KA and Harden TK (1998) Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate. *Br J Pharmacol* **124**:1-3.
- Braun N, Zhu Y, Krieglstein J, Culmsee C and Zimmermann H (1998) Upregulation of the enzyme chain hydrolyzing extracellular ATP after transient forebrain ischemia in the rat. *J Neurosci* **18**:4891-4900.
- Bucheimer RE and Linden J (2004) Purinergic regulation of epithelial transport. J Physiol 555:311-321.
- Chhatriwala M, Ravi RG, Patel RI, Boyer JL, Jacobson KA and Harden TK (2004) Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. *J Pharm Exp Ther* **311**:1038-1043.

- Choi RC, Siow NL, Cheng AW, Ling KK, Tung EK, Simon J, Barnard EA and Tsim KW (2003) ATP acts via P2Y1 receptors to stimulate acetylcholinesterase and acetylcholine receptor expression: transduction and transcription control. *J Neurosci* 23:4445-4456.
- Dubyak GR and el-Moatassim C (1993) Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. *Am J Physiol* **265**.
- Fries JE, Wheeler-Schilling TH, Guenther E and Kohler K (2004) Expression of P2Y1, P2Y2, P2Y4, and P2Y6 receptor subtypes in the rat retina. *Invest Ophthalm Vis Sci* **45**:3410-3417.
- Gregory CY, Abrams TA and Hall MO (1994) Stimulation of A2 adenosine receptors inhibits the ingestion of photoreceptor outer segments by retinal pigment epithelium. *Invest Ophthalmol Vis Sci* **35**:819-825.
- Grygorczyk R and Hanrahan JW (1997) CFTR-independent ATP release from epithelial cells triggered by mechanical stimuli. *Am J Physiol Cell Physiol* **272**:C1058-1066.
- Hechler B, Nonne C, Roh EJ, Cattaneo M, Cazenave JP, Lanza F, Jacobson KA and Gachet C (2006) MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. *J Pharmacol Exp Therapeut* **316**:556-563.
- Houston D, Ohno M, Nicholas RA, Jacobson KA and Harden TK (2006) [32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors. *Br J Pharmacol* **147**:459-467.
- Kaczmarek E, Koziak K, Sevigny J, Siegel JB, Anrather J, Beaudoin AR, Bach FH and Robson SC (1996) Identification and characterization of CD39/vascular ATP diphosphohydrolase. *J Biol Chem* **271**:33116-33122.
- Kim HS, Ohno M, Xu B, Kim HO, Choi Y, Ji XD, Maddileti S, Marquez VE, Harden TK and Jacobson KA (2003) 2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. *J Med Chem* **46**:4974-4987.

- Lazarowski ER, Boucher RC and Harden TK (2003) Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. *Mol Pharmacol* **64**:785-795.
- Lemmens R, Vanduffel L, Kittel A, Beaudoin AR, Benrezzak O and Sevigny J (2000) Distribution, cloning, and characterization of porcine nucleoside triphosphate diphosphohydrolase-1. *Eur J Biochem* **267**:4106-4114.
- Maminishkis A, Jalickee S, Blaug SA, Rymer J, Yerxa BR, Peterson WM and Miller SS (2002) The P2Y2 receptor agonist INS37217 stimulates RPE fluid transport in vitro and retinal reattachment in rat. *Invest Ophthalmol Vis Sci* **43**:3555-3566.
- Mitchell CH (2001) Release of ATP by a human retinal pigment epithelial cell line: potential for autocrine stimulation through subretinal space. *J Physiol* **534**:193-202.
- Mitchell CH and Reigada D (In press) Purinergic signalling in the subretinal space: a role in the communication between the retina and the RPE. *Purinergic Signalling* 10.1007/s11302-007-9054-2.
- Peterson WM, Meggyesy C, Yu K and Miller SS (1997) Extracellular ATP activates calcium signaling, ion, and fluid transport in retinal pigment epithelium. *J Neurosci* **17**:2324-2337.
- Picher M, Sevigny J, D'Orleans-Juste P and Beaudoin AR (1996) Hydrolysis of P2-purinoceptor agonists by a purified ectonucleotidase from the bovine aorta, the ATP-diphosphohydrolase. *Biochem Pharmacol* **51**:1453-1460.
- Reigada D, Lu W and Mitchell CH (2006a) Glutamate acts at NMDA receptors on fresh bovine and on cultured human retinal pigment epithelial cells to trigger release of ATP. *J Physiol* **575**:707-720.
- Reigada D, Lu W, Zhang X, Friedman C, Pendrak P, McGlinn A, Stone RA, Laties A.M and Mitchell CH (2005) Degradation of extracellular ATP by the retinal pigment epithelium. *Am J Physiol Cell Physiol* **289**:C617-C624.
- Reigada D and Mitchell CH (2005) Release of ATP from RPE cells involves both CFTR and vesicular

- transport. Am J Physiol Cell Physiol 288:C132-C140.
- Reigada D, Zhang X, Crespo A, Nguyen J, Liu J, Pendrak K, Stone RA, Laties AM and Mitchell CH (2006b) Stimulation of an α1-adrenergic receptor downregulates ecto-5' nucleotidase activity on the apical membrane of RPE cells. *Purinergic Signalling* **2**:499-507.
- Robson SC, Sévigny J and Zimmermann H (2006) The E-NTPDase family of ectonucleotidases:

 Structure, function, relationships and pathophysiological significance. *Purinergic Signalling*2:409-430.
- Schetinger MR, Barcellos CK, Barlem A, Zwestch G, Gubert A, Bertuol C, Arteni N, Dias RD, Sarkis JJ and Netto CA (1994) Activity of synaptosomal ATP diphosphohydrolase from hippocampus of rats tolerant to forebrain ischemia. *Braz J Med Biol Res* 27:1123-1128.
- Schulte am Esch J, 2nd, Sevigny J, Kaczmarek E, Siegel JB, Imai M, Koziak K, Beaudoin AR and Robson SC (1999) Structural elements and limited proteolysis of CD39 influence ATP diphosphohydrolase activity. *Biochem* **38**:2248-2258.
- Schwiebert EM (2001) ATP release mechanisms, ATP receptors and purinergic signalling along the nephron. *Clin Exp Pharm Physiol* . **28**:340-350.
- Sevigny J, Cote YP and Beaudoin AR (1995) Purification of pancreas type-I ATP diphosphohydrolase and identification by affinity labelling with the 5'-p-fluorosulphonylbenzoyladenosine ATP analogue. *Biochem J* **312**:351-356.
- Sevigny J, Levesque FP, Grondin G and Beaudoin AR (1997) Purification of the blood vessel ATP diphosphohydrolase, identification and localisation by immunological techniques. *Biochim Biophys Acta* 1:73-88.
- Strauss O (2005) The retinal pigment epithelium in visual function. *Physiol Rev* **85**:845-881.
- Vlajkovic SM, Housley GD, Munoz DJ, Robson SC, Sevigny J, Wang CJ and Thorne PR (2004) Noise exposure induces up-regulation of ecto-nucleoside triphosphate diphosphohydrolases 1 and 2 in rat cochlea. *Neurosci* **126**:763-773.
- von Kugelgen I (2006) Pharmacological profiles of cloned mammalian P2Y-receptor subtypes.

Pharmacol Therapeut 110:415-432.

- Wiendl HS, Schneider C and Ogilvie A (1998) Nucleotide metabolizing ectoenzymes are upregulated in A431 cells periodically treated with cytostatic ATP leading to partial resistance without preventing apoptosis. *Biochim Biophys Acta* **3**:282-298.
- Wood E, Johan Broekman M, Kirley TL, Diani-Moore S, Tickner M, Drosopoulos JH, Islam N, Park JI, Marcus AJ and Rifkind AB (2002) Cell-type specificity of ectonucleotidase expression and upregulation by 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Arch Biochem Biophys* **407**:49-62.
- Zhang M, Budak MT, Lu W, Khurana TS, Zhang X, Laties AM and Mitchell CH (2006a) Identification of the A3 adenosine receptor in rat retinal ganglion cells. *Mol Vis* **12**:937-948.
- Zhang X, Zhang M, Laties AM and Mitchell CH (2006b) Balance of purines may determine life or death as A3 adenosine receptors prevent loss of retinal ganglion cells following P2X7 receptor stimulation. *J Neurochem* **98**:566-575.

Footnotes

This work was supported by NIH grants EY013434 and EY015537 to CHM, and a Core Vision Grant EY001583 to the University of Pennsylvania. JS is supported by the Canadian Institutes of Health Research (CIHR) and is also the recipient of a New Investigator award from CIHR.

A preliminary version of some of these results has been presented in abstract form. Lu W., Reigada D., Sévigny J., Mitchell C.H. (2006) *Invest Ophthalmol Vis Sci* **47**: 382

Address correspondence to: Dr. Claire H. Mitchell, Department of Physiology, University of Pennsylvania, 3700 Hamilton Walk, Philadelphia, PA 19104-6085, Tel. 215 573-2176; Fax. 215 573-5851, E-mail:chm@mail.med.upenn.edu

Legends for Figures

Fig 1. RT-PCR for NTPDase1 from human ARPE-19 cells. (A) PCR with a primer pair specific for NTPDase1 generated a 558-bp band in cDNA from cells treated with ATPγS for 48 hrs, but not in untreated control cells. The band intensity increased with the starting volume of cDNA. (B) The densitometric values of the RT-PCR amplified NTPDase1 products increased linearly with an increasing amount of cDNA in cells exposed to 100 μM ATPγS (black circles). No product was detected from cells in control medium (white triangles). A first order linear regression is fit to the data. Similar increases in NTPDase1 message were found in three independent sets of cells exposed to ATPγS for 48 hrs, and in all cases densitometetric values increased with the amount of cDNA. (C) PCR with β-actin primer pair generated single 244-bp bands in both control and ATPγS treated cells. (D) The densitometric values of β-actin products increased linearly in both ATPγS-treated (black circles) and control cells (white triangles). Data are fit with a single order regression. (E, F) Time-course of upregulation of NTPDase1 mRNA. Cells were exposed to ATPγS continuously for the time indicated. Message for NTPDase1 was first detected after 12 hrs exposure to ATPγS, while levels of β-actin remained constant throughout. NTPDase1 data points are connected with a line. A similar time course was found in 3 independent trials.

Fig 2. Quantitative PCR analysis of NTPDase1 expression in RPE cells. Amplification of NTPDase1 in RPE cells exposed to control or $100 \mu M$ ATPγS medium for 48 hrs was performed with SYBR Green real-time PCR. cDNA samples were diluted 1/10 and all reactions performed in triplicate. The CT of housekeeping gene β-actin was similar for both control and ATPγS treated cells (lines 1 and 2 respectively), whereas CT for the NTPDase1 message was attained after considerably fewer amplification cycles in ATPγS treated cells (line 3) as compared with untreated cells (line 4). No signal was detected from the no-template control (line 5). Similar increases were found using message from three independent

Downloaded from jpet.aspetjournals.org at ASPET Journals on April 19, 2024

JPET #124545

trials, each performed in triplicate. The figure indicates the mean of such triplicate reactions from one

particular trial.

Fig. 3. Western blot analysis for NTPDase1 protein levels. (A) Immunobloting with antibody BU61

demonstrates that incubation of cells with 100 µM ATPγS for 48 hrs led to detectable 78 kDa bands in

protein from whole cell lysates. (B). 78 kDa bands were also detected in protein purified from cell

membranes after incubation with 100 μM ATPγS for 48 hrs. (C). Incubation of cells with 100 μM ATPγS

for 12, 24 and 48 hrs led to detectable 78 kDa bands on immunoblots of increasing intensity from cell

lysate material. (D) Quantification of staining intensity indicates that the largest increase in NTPDase1

protein occurred after 12 to 24 hrs of exposure to ATPyS. A similar increase in NTPDase1 protein levels

after 24 hrs in ATPyS was found in 14 trials.

Fig 4. Incubation with ATPyS increased ecto-ATPase activity. (A) Cells exposed to 100 µM ATPyS for

48 hrs (gray triangles) hydrolyzed 1 µM ATP more rapidly than untreated control cells (black circles).

Intermediate preincubations of 15 and 24 hrs led to intermediate increases in hydrolysis but are not shown

here for reasons of clarity. Results show the mean of 5-8 wells from a trial representative of 3

independent experiments. Light levels represent the photons given off with the luciferin/luciferase

reaction, an index of the level of ATP present in the bath (in arbitrary units, A.U.). (B) The time constant

of decay decreased exponentially with preincubation time. * p<0.05 vs. no preincubation, n=5-8. In (A),

error bars are smaller than symbols.

Fig 5. Involvement of P2Y₁ receptors in upregulation of NTPDase1. P2 antagonists were given to cells 10

min before 100 µM ATPyS and the 78 kDa band detected with antibody BU61 from protein extracted

from whole cell lysates 24 hrs later. (A) Non-specific P2 antagonist oATP (100 µM) decreased the net

upregulation of NTPDase1 by 25%. The upper trace is representative of 4 independent trials, with the

26

JPET Fast Forward. Published on July 12, 2007 as DOI: 10.1124/jpet.107.124545 This article has not been copyedited and formatted. The final version may differ from this version.

JPET #124545

mean \pm SE given in the bars below. (B) The effect of RB2 (50 μ M) was variable with some trials like that illustrated above indicating a drastic reduction, although the mean decrease was not significant (n=8). (C) The P2Y₁ receptor antagonist MRS2179 (100 μ M) led to a clear decrease in band intensity (n=7). (D) A second P2Y₁ antagonist, MRS2500 (10 nM), also decreased band intensity (n=4). (E) P2Y₁ agonists MRS2365 (100 nM) significantly increased NTPDase1 levels compared to control after 24 hrs exposure, while the rise with 100 μ M 2MeSATP was not significant (n=2-3). * p<0.05 vs. ATP γ S alone (A-D) or vs. control (E).

Figure 1




Figure 2 Fluorescence(\Delta Rn) 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40

Figure 3





Figure 4






Figure 5

